doi:10.16150/j.1671-2870.2020.03.022

Abstract

CLC Number:

R737.9

References 39

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. doi: 10.3322/caac.21590 URL
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.21492 URL
[3]	Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer[J]. Breast, 2015, 24( Suppl 2):S26-S35.
[4]	Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: Updated review[J]. Ochsner J, 2017, 17(4):405-411.
[5]	Ma CX, Bose R, Ellis MJ. Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer[J]. Adv Exp Med Biol, 2016, 882:125-154.
[6]	Asif HM, Sultana S, Ahmed S, et al. HER-2 positive breast cancer-a mini-review[J]. Asian Pac J Cancer Prev, 2016, 17(4):1609-1615. doi: 10.7314/APJCP.2016.17.4.1609 URL
[7]	Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer[J]. Jama Oncol, 2015, 1(8):1154-1161. doi: 10.1001/jamaoncol.2015.2286 pmid: 26204261
[8]	Wang W, Wu J, Zhang P, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer[J]. Oncotarget, 2016, 7(21):31079-31087. doi: 10.18632/oncotarget.9075 pmid: 27145269
[9]	Mb A, Sb E, Fl G, et al. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2016:589-628.
[10]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8):609-679.
[11]	彭晓静, 李奥, 叶新华, 等. 应变式弹性成像与剪切波弹性成像技术鉴别诊断乳腺良恶性病灶的价值比较[J]. 中华医学超声杂志(电子版), 2016, 13(12):942-947. doi: 10.3877/cma.j.issn.1672-6448.2016.12.013
[12]	You Y, Song Y, Li SX, et al. Quantitative and qualitative evaluation of breast cancer prognosis: A sonographic elastography study[J]. Med Sci Monit, 2019, 25:9272-9279. doi: 10.12659/MSM.918806 URL
[13]	Hayashi M, Yamamoto Y, Sueta A, et al. Associations between elastography findings and clinicopathological factors in breast cancer[J]. Medicine (Baltimore), 2015, 94(50):e2290. doi: 10.1097/MD.0000000000002290 URL
[14]	Chang JM, Park IA, Lee SH, et al. Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer[J]. Eur Radiol, 2013, 23(9):2450-2458. doi: 10.1007/s00330-013-2866-2 pmid: 23673574
[15]	Youk JH, Gweon HM, Son EJ, et al. Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemi-cal profile[J]. Breast Cancer Res Treat, 2013, 138(1):119-126. doi: 10.1007/s10549-013-2407-3 URL
[16]	Brocklehurst D, Wilde CE, Finbow JA, et al. Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: a short-term study[J]. Clin Chem, 1989, 35(2):238-240. pmid: 2914367
[17]	Au FWF, Ghai S, Lu FI, et al. Quantitative shear wave elastography: correlation with prognostic histologic features and immunohistochemical biomarkers of breast cancer[J]. Acad Radiol, 2015, 22(3):269-277. doi: 10.1016/j.acra.2014.10.007 URL
[18]	Choi WJ, Kim HH, Cha JH, et al. Predicting prognostic factors of breast cancer using shear wave elastography[J]. Ultrasound Med Biol, 2014, 40(2):269-274. doi: 10.1016/j.ultrasmedbio.2013.09.028 URL
[19]	Gonzalez-Sistal A, Baltasar-Sánchez A, Menéndez P, et al. Breastfeeding and immunohistochemical expression of ki-67, p53 and BCL2 in infiltrating lobular breast carcinoma[J]. PloS One, 2016, 11(3):e151093.
[20]	Raja R, Kale S, Thorat D, et al. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis[J]. Oncogene, 2014, 33(16):2053-2064. doi: 10.1038/onc.2013.171 pmid: 23728336
[21]	Cao Y, Guangqi E, Wang E, et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression[J]. Cancer Res, 2012, 72(16):3912-3918.
[22]	Guo R, Lu G, Qin B, et al. Ultrasound imaging technologies for breast cancer detection and management: A review[J]. Ultrasound Med Biol, 2018, 44(1):37-70. doi: 10.1016/j.ultrasmedbio.2017.09.012 URL
[23]	Vraka I, Panourgias E, Sifakis E, et al. Correlation between contrast-enhanced ultrasound characteristics (qua-litative and quantitative) and pathological prognostic factors in breast cancer[J]. In Vivo, 2018, 32(4):945-954. doi: 10.21873/invivo.11333 URL
[24]	Cao XL, Bao W, Zhu SG, et al. Contrast-enhanced ultrasound characteristics of breast cancer: Correlation with prognostic factors[J]. Ultrasound Med Biol, 2014, 40(1):11-17. doi: 10.1016/j.ultrasmedbio.2013.08.014 URL
[25]	Wan CF, Du J, Fang H, et al. Enhancement patterns and parameters of breast cancers at contrast-enhanced US: Correlation with prognostic factors[J]. Radiology, 2012, 262(2):450-459. doi: 10.1148/radiol.11110789 URL
[26]	Putti TC, El-Rehim DM A, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis[J]. Mod Pathol, 2004, 18(1):26-35. doi: 10.1038/modpathol.3800255 URL
[27]	Zhao LX, Liu H, Wei Q, et al. Contrast-enhanced ultrasonography features of breast malignancies with different sizes: Correlation with prognostic factors[J]. Biomed Res Int, 2015, 2015:613831.
[28]	Zhao YX, Liu S, Hu YB, et al. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study[J]. Onco Targets Ther, 2017, 10:1123-1129. doi: 10.2147/OTT.S124134 URL
[29]	Lichtenbeld HC, Barendsz-Janson AF, Essen HV, et al. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model[J]. Int J Cancer, 1998, 77(3):455-459. pmid: 9663610
[30]	Ji CL, Li X, He Y, et al. Quantitative parameters of contrast-enhanced ultrasound in breast invasive ductal carcinoma: The correlation with pathological prognostic factors[J]. Clin Hemorheol Microcirc, 2017, 66(4):333-345. doi: 10.3233/CH-170251 URL
[31]	Szabó BK, Saracco A, Tánczos E, et al. Correlation of contrast-enhanced ultrasound kinetics with prognostic factors in invasive breast cancer[J]. Eur Radiol, 2013, 23(12):3228-3236. doi: 10.1007/s00330-013-2960-5 URL
[32]	Nie M, Qin YC, Zhu JF, et al. Correlation between ultrasonic features and expression levels of C-erbB-2, VEGF and nm23 in breast cancer[J]. Oncol Lett, 2018, 16(2):1701-1707.
[33]	朱琳, 张丽华, 吴道明, 等. 超声光散射成像系统对各种病理类型乳腺病变的诊断价值[J]. 中国超声医学杂志, 2016, 32(10):883-886.
[34]	Mostafa A, Vavadi H, Uddin KMS, et al. Diffuse optical tomography using semiautomated coregistered ultrasound measurements[J]. J Biomed opt, 2017, 22(12):1-12. doi: 10.1117/1.JBO.22.12.121610 pmid: 29260537
[35]	Kim MJ, Su MY, Yu HJ, et al. US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers[J]. BMC Cancer, 2016, 16(1):50. doi: 10.1186/s12885-016-2086-7 URL
[36]	Zhi WX, Wang Y, Chang C, et al. US-guided diffuse optical tomography: Clinicopathological features affect total hemoglobin concentration in breast cancer[J]. Trasl Oncol, 2018, 11(4):845-851.
[37]	Zhu Q, Hegde PU, Ricci A, et al. Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis[J]. Radiology, 2010, 256(2):367-378. doi: 10.1148/radiol.10091237 URL
[38]	Choi JS, Kim MJ, Youk JH, et al. US-Guided optical tomography: Correlation with clinicopathologic variables in breast cancer[J]. Ultrasound Med Biol, 2013, 39(2):233-240. doi: 10.1016/j.ultrasmedbio.2012.09.014 pmid: 23219038
[39]	Brown JQ, Wilke LG, Geradts J, et al. Quantitative optical spectroscopy: A robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo[J]. Cancer Res, 2009, 69(7):2919-2926 doi: 10.1158/0008-5472.CAN-08-3370 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 39

Related Articles 13

Recommended Articles

Metrics

Comments

[1]	HOU Xiaosa, YANG Zhenjiang. Risk factors of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(03): 284-289.
[2]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(03): 294-297.
[3]	LI Weiwei, WU Ying, ZHOU Wei, ZHAN Weiwei, ZHOU Qinghua, TAO Lingling, YANG Yanwen. The diagnostic value of smart three-dimensional superb microvascular imaging in differentiating benign and malignant breast lesions of BI-RADS 4 [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(06): 583-587.
[4]	YAN Bing, WANG Haifei, CAO Yunyun, NIU Jianmei. Comparative analysis of ultrasonographic features and clinicopathological types for mucinous breast carcinoma and analysis of the causes for misdiagnosis [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 386-390.
[5]	LI Weiwei, ZHAN Weiwei, ZHOU Wei, TAO Lingling, WANG Yi, FAN Jinfang, FEI Yuanxin, KUANG Lijun, XU Wenying. The diagnostic value of smart three-dimensional superb microvascular imaging in detecting blood flow distribution pattern of breast lesion [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 139-143.
[6]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 223-227.
[7]	WANG Shunli, DENG Shuangshuang, GAO Hui, XIAO Tianyu, GAO Jinli. Analysis of clinicopathological characteristics of breast encapsulated papillarycarcinoma [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 89-92.
[8]	YAO Jiejie, ZHU Ying, ZHAN Weiwei, CHEN Xiaosong, FEI Xiaochun. Correlation of sonographic features of non-mass ductal carcinoma in situ with clinicopathological findings and biomarkers [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(06): 676-681.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(02): 225-230.
[10]	WU Yan, DING Peifen, GU Yan, GUO Shanyu, DAI Qiancheng, ZHANG Wei. Expression and analysis of HIC-1 and HMMR in breast cancer [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(01): 73-78.
[11]	DA Qian, WU Dongmei, XU Haimin, WANG Chaofu. Clinicopathological characteristics of adenoid cystic carcinoma in breast: report of 10 cases and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(06): 608-613.
[12]	. [J]. Journal of Diagnostics Concepts & Practice, 2016, 15(05): 528-531.
[13]	PEI Wenjiang, ZHAO Feng, WU Yan, ZHONG Ming, GAO Hang, LI Yousheng, GU Yan, GUO Shanyu, DAI Qiancheng, ZHANG Wei. Effect of hypermethylated in cancer 1-downstream-regulated gene HMMR on cell migration and invasion in breast cancer: an in vitro study on breast cancer cell line MDA-MB-231 [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 70-75.